Compare TIVC & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIVC | ALBT |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.3M |
| IPO Year | 2021 | 2015 |
| Metric | TIVC | ALBT |
|---|---|---|
| Price | $1.40 | $0.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 133.1K | ★ 545.0K |
| Earning Date | 05-14-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.18 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $780,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.75 | $0.21 |
| 52 Week High | $5.60 | $4.74 |
| Indicator | TIVC | ALBT |
|---|---|---|
| Relative Strength Index (RSI) | 69.31 | 33.01 |
| Support Level | $0.79 | N/A |
| Resistance Level | $2.70 | $0.43 |
| Average True Range (ATR) | 0.11 | 0.04 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 100.00 | 54.25 |
Tivic Health Systems Inc is a late-stage biopharmaceutical company focused on the development of biologics, with its lead product candidate, Entolimod, a TLR5 agonist, being developed for acute radiation syndrome and oncology-related indications. The company operates through two segments: a biopharma segment focused on product development and commercialization, and a contract development and manufacturing organization (CDMO) segment providing manufacturing and development services through its subsidiary.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.